2017
DOI: 10.1186/s40409-017-0109-8
| View full text |Cite
|
Sign up to set email alerts
|

Abstract: Hemostatic and adhesive agents date back to World War II, when homologous fibrin sealant came onto scene. Considering that infectious diseases can be transmitted via human blood, a new heterologous fibrin sealant was standardized in the 1990s. Its components were a serine protease (a thrombin-like enzyme) extracted from the venom of Crotalus durissus terrificus snakes and a fibrinogen-rich cryoprecipitate extracted from the blood of Bubalus bubalis buffaloes. This new bioproduct has been used as a coagulant, s… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
76
1

Year Published

2017
2017
2023
2023

Publication Types

Select...
8
1

Relationship

4
5

Authors

Journals

citations
Cited by 63 publications
(77 citation statements)
references
References 54 publications
0
76
1
Order By: Relevance
“…To overcome these challenges, the Center for the Study of Venoms and Venomous Animals (CEVAP) from São Paulo State University (UNESP), Sao Paulo, Brazil, has been studying and developing heterologous fibrin biopolymer (HFB) from animal origin materials since the 1990s. This heterologous biomaterial is biocompatible, having hemostatic, adhesive, sealant, scaffold and drug delivery properties [9][10][11]. This bioproduct is being successfully tested in reconstruction processes when applied to various tissues [6,[12][13][14][15].…”
Section: Introductionmentioning
confidence: 99%
“…To overcome these challenges, the Center for the Study of Venoms and Venomous Animals (CEVAP) from São Paulo State University (UNESP), Sao Paulo, Brazil, has been studying and developing heterologous fibrin biopolymer (HFB) from animal origin materials since the 1990s. This heterologous biomaterial is biocompatible, having hemostatic, adhesive, sealant, scaffold and drug delivery properties [9][10][11]. This bioproduct is being successfully tested in reconstruction processes when applied to various tissues [6,[12][13][14][15].…”
Section: Introductionmentioning
confidence: 99%
“…Commercially available fibrin biopolymers, also called fibrin sealants, consist of human fibrinogen and thrombin. The BPF used in this study is composed of a mixture of a serine protease with thrombin-like enzyme activity, purified from Crotalus durissus terrificus snake venom and buffaloes cryoprecipitate as a source of fibrinogen 53, 30 . Previous studies has shown no cytotoxicity becoming an excellent scaffold for MSC 16, 34, 54, 55 .…”
Section: Discussionmentioning
confidence: 99%
“…A new fibrin biopolymer (FBP) constituted of two animal derived compounds instead of human blood has been used in experimental biomedical applications 24,26, 27, 28, 29, 30, 31 , such as nervous tissue 32,33 and bone 34 repair as also on the treatment of chronic venous ulcers in human patients 30,33 .…”
Section: Introductionmentioning
confidence: 99%
“…At the time in experimental surgery, the components were first thawed, then reconstituted, mixed, and applied according to the following protocol: The first bottle (Eppendorf®) contained fibrinogen obtained from buffalo blood (5 μl); the second contained calcium chloride (2 μl); and the last bottle contained a thrombin-like fraction (1 μl); for a total of 8 μl. The production process was described in Ferreira Junior et al [41].…”
Section: New Heterologous Fibrin Sealantmentioning
confidence: 99%